Los Angeles Capital Management
DYN icon

Los Angeles Capital Management’s Dyne Therapeutics DYN Stock Holding History

Los Angeles Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.15K Sell
322
-290
-47% -$5.39K ﹤0.01% 2037
2026
Q1 		$11.1K Sell
612
-13,080
-96% -$226K ﹤0.01% 1919
2025
Q4 		$322K Buy
+13,692
New +$259K ﹤0.01% 1060

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Los Angeles Capital Management's DYN Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Dyne Therapeutics (DYN) stake by 47% in Q2 2026, selling an estimated $5.39K and leaving 322 shares worth $7.15K. The position accounts for ﹤0.01% of the portfolio, ranked #2037.

Los Angeles Capital Management first reported a position in DYN in Q4 2025 and has held it in 3 quarters since. The position peaked at $322K in Q4 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Los Angeles Capital Management held 322 shares of Dyne Therapeutics worth $7.15K as of Q2 2026.
  • Los Angeles Capital Management sold 290 Dyne Therapeutics shares in Q2 2026, an estimated $5.39K.
  • Dyne Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #2037 holding.
  • Los Angeles Capital Management first reported a position in Dyne Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Los Angeles Capital Management's Dyne Therapeutics position peaked at $322K in Q4 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.